Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 13/20 | 0.84 |
| ▸ | LPAR2 | Q9HBW0 | 9/20 | 0.84 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.84 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6810040 | 1.00 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL29026467 | 1.00 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL4247095 | 1.00 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18444275 | 1.00 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL29026510 | 1.00 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL4483106 | 1.00 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18444519 | 1.00 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL27619288 | 0.98 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL28711361 | 0.98 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL28936054 | 0.98 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0354323-A2 | Antidiabetic phosphates | AMERICAN CYANAMID COMPANY (US) | 1990-02-14 | — | — | EP | claimed |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | UNIV CALIFORNIA (US) | 2025-01-09 | — | — | US | disclosed |
| US-12173029-B2 | Antiviral prodrugs, pharmaceutical formulations, and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4469061-A2 | ANTIVIRAL PRODRUGS, INTERMEDIATE- AND LONG-ACTING FORMULATIONS AND METHODS | The Regents of the University of California (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024159117-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20240043467-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
| CN-116554249-A | Antiviral compounds and uses thereof | 北京恩泰伟医药科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2022047400-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022020793-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-27 | — | — | WO | disclosed |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| EP-3676276-A1 | SPIROTHIETANE NUCLEOSIDES | Janssen Pharmaceutica NV (BE) | 2020-07-08 | — | — | EP | disclosed |
| CN-111051325-A | Spirothiacyclobutanenucleosides | 詹森药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-110655546-A | Sofosbuvir derivative and preparation method and application thereof | 安徽贝克联合制药有限公司 | 2020-01-07 | — | — | CN | disclosed |
| WO-2019043177-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | WO | disclosed |
| US-8017135-B1 | Lipid-drug conjugates for local therapy of eye diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-13 | — | — | US | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| WO-2006130217-A2 | SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | LPAR3 2076/4885LPAR2 2121/4885LPAR1 1954/4885 |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | LPAR3 636/4885LPAR2 451/4885LPAR1 853/4885 |
| US-12173029-B2 | Antiviral prodrugs, pharmaceutical formulations, and methods | MTAP, SARS1, RNGTT | LPAR3 2740/4885LPAR2 3503/4885LPAR1 2440/4885 |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | SARS1, ACE2, FURIN | LPAR3 823/4885LPAR2 389/4885LPAR1 468/4885 |
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | LPAR3 2740/4885LPAR2 3503/4885LPAR1 2440/4885 |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | SAMHD1, SLC28A1, SLC28A2 | LPAR3 2937/4885LPAR2 3681/4885LPAR1 3590/4885 |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | LPAR3 2740/4885LPAR2 3503/4885LPAR1 2440/4885 |
| US-20240043467-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | PNP, ENTPD5, TYMP | LPAR3 1201/4885LPAR2 1416/4885LPAR1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.